U.S. markets closed

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.7300+0.0300 (+1.76%)
At close: 11:49AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.6850 - 1.7300
52 Week Range1.5800 - 4.9800
Avg. Volume20,893
Market Cap15.073M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more

    Pressure BioSciences, Inc. Reports Q1 2022 Financial Results

    Focused on the Successful Launch of its "Early Access Program" for the UST Platform, Company Already Negotiating with Four Potential Customers for Nanoemulsion Processing in Nutraceuticals and CosmeticsInvestor Call Scheduled for Thursday, May 19, 2022 at 4:30 p. ETSOUTH EASTON, MA / ACCESSWIRE / May 19, 2022 / Pressure BioSciences, Inc.


    Pressure BioSciences Announces First Nanoemulsions Manufacturing Agreement Under Recently Released UST Early Access Program

    Company Signs Development & Manufacturing Agreement with Safer Medical of Montana for Formulation, Pilot Batches, and Commercial Production of CBD Topical Spray for Pain ReductionSOUTH EASTON, MA / ACCESSWIRE / May 4, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agr


    Pressure BioSciences to Present at the Planet MicroCap Showcase 2022 on May 4, 2022

    Company Invites Investors, Analysts, and Advisors to Attend Its In-Person and Webcast Presentation on Wednesday, May 4, 2022 at 11:30am PDTSOUTH EASTON, MA / ACCESSWIRE / May 3, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, nutraceuticals, agrochem, and food & beverage industries, today an